Piergiorgio Chiodini
University of Pavia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Piergiorgio Chiodini.
Psychoneuroendocrinology | 1992
Emilia Martignoni; Alfredo Costa; Elena Sinforiani; Antonio Liuzzi; Piergiorgio Chiodini; Marco Mauri; Giorgio Bono; Giuseppe Nappi
It is well established that a reciprocal control exists between the brain and glucocorticoid hormones. The brain regulates adrenocortical function via hypothalamic corticotrophin releasing hormone-41 (CRH-41), glucocorticoids act at specific receptors in the hippocampus, thus promoting negative feedback mechanisms. Because the hippocampus is a major site for memory processes, a role for excessive/long-lasting plasma glucocorticoid levels has been suggested in conditions of mental impairment. Major depression, Cushings disease, and dementia of the Alzheimer type are disorders which share hyperactivity of the hypothalamo-pituitary-adrenal axis, as well as symptoms of cognitive decline. Although the mechanisms leading to hypercortisolemia appear to be different in each case, the neuropsychological features of these three disorders accord with the hypothesis of glucocorticoid-associated brain damage. It therefore is important to find pharmacological strategies that will avert or reduce these potential consequences on brain function.
The New England Journal of Medicine | 1985
Antonio Liuzzi; Daniela Dallabonzana; Giuseppe Oppizzi; Giuseppe Verde; Renato Cozzi; Piergiorgio Chiodini; Giovanni Luccarelli
To evaluate the long-term effects of dopamine agonists in the treatment of macroprolactinoma, we studied prolactin levels and tumor size for 30 to 88 months (57 +/- 14, mean +/- S.D.) in 38 patients treated with bromocriptine or lisuride. Elevated prolactin levels became normal in 30 patients, and the tumor shrank in 29. After two years of treatment, we attempted to reduce the maintenance dose (5 to 20 mg of bromocriptine per day or 0.4 to 0.8 mg of lisuride per day); in 21 patients no changes in prolactin levels or tumor size were observed over 6 to 52 months with 0.625 to 10 mg of bromocriptine per day or 0.05 mg of lisuride per day. However, it was possible to withdraw the drug in only one patient. We conclude that dopamine agonists are usually effective treatments for macroprolactinoma and that after a response has been obtained, it can be maintained in many patients with a greatly reduced dose.
The Journal of Clinical Endocrinology and Metabolism | 1974
A. Liuzzi; Piergiorgio Chiodini; L. Botalla; G. Cremascoli; E. E. Müller; F. Silvestrini
The Journal of Clinical Endocrinology and Metabolism | 1981
Piergiorgio Chiodini; Antonio Liuzzi; Renato Cozzi; Giuseppe Verdexs; Giuseppe Oppizzi; Daniela Dallabonzana; Barbara Spelta; F. Silvestrini; Giampaola Borghi; Giuseppe Luccarelli; Ernst Rainer; Reinhardt Horowski
The Journal of Clinical Endocrinology and Metabolism | 1972
A. Liuzzi; Piergiorgio Chiodini; L. Botalla; G. Cremascoli; F. Silvestrini
The Journal of Clinical Endocrinology and Metabolism | 1974
A. Liuzzi; Piergiorgio Chiodini; L. Botalla; F. Silvestrini; E. E. Müller
The Journal of Clinical Endocrinology and Metabolism | 1974
Piergiorgio Chiodini; A. Liuzzi; L. Botalla; G. Cremascoli; F. Silvestrini
The Journal of Clinical Endocrinology and Metabolism | 1976
Piergiorgio Chiodini; A. Liuzzi; E. E. Muller; L. Botalla; G. Cremascoli; Giuseppe Oppizzi; Giuseppe Verde; F. Silvestrini
The Journal of Clinical Endocrinology and Metabolism | 1986
Giuseppe Oppizzi; M. M. Petroncini; Daniela Dallabonzana; Renato Cozzi; Giuseppe Verde; Piergiorgio Chiodini; A. Liuzzi
The Journal of Clinical Endocrinology and Metabolism | 1984
Giuseppe Oppozzi; Antonio Liuzzi; Piergiorgio Chiodini; Dallabonzana Daniela; Barbara Spelta; F. Silvestrini; Gimpaolo Borghi; Cristina Tonon